Incretin Atlas › Trials › ACHIEVE-4
ACHIEVE-4
Orforglipron · T2D at increased CV risk (86 % established CVD, 38 % CKD), t2d
Design
- Molecule(s)
- Orforglipron
- Population
- T2D at increased CV risk (86 % established CVD, 38 % CKD), t2d
- Official title
- A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
- Sponsor
- Eli Lilly and Company
- Phase
- 3
- Registry status
- completed · 2023-04 → 2026-03
- Participants
- 2749
- Duration
- 52 weeks
- Registry
- NCT05803421
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| orforglipron 36 mg or MTD vs insulin glargine (active) | t2d | 52 | — | −8.8 % | −7.8 % | −1.5 | 15.4 | 30.9 vs 20.5 | 31.9 | 21.0 | 16.2 | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- orforglipron 36 mg or MTD: Active comparator insulin glargine: weight +1.66 % (efficacy) / +1.12 % (treatment-policy), HbA1c −0.96, AE discontinuation 5.4 %, nausea 1.4 %, vomiting 1.6 %, SAE 18.8 %. Safety and discontinuation cover the whole on-treatment period (to week 104 or later); any discontinuation derived from «completed on treatment».
Verbatim quotes from the source (7)
- orforglipron 36 mg or MTD · weight_eff · Table (week 52)
52 | -8.76% | 1.66%
- orforglipron 36 mg or MTD · hba1c · Table (week 52)
Orforglipron | -1.46
- orforglipron 36 mg or MTD · disc_any · Results, disposition
2044 (74·4%) of 2749 completed the study on treatment (948 [69·1%] of 1371 assigned to orforglipron and 1096 [79·5%] of 1378 assigned to insulin glargine). The
- orforglipron 36 mg or MTD · ae_dc · Table 3 (orforglipron n=1371, insulin glargine n=1355; on-tr
Adverse events leading to study treatment discontinuation 211 (15·4%) 73 (5·4%)
- orforglipron 36 mg or MTD · nausea · Table 3 (orforglipron n=1371, insulin glargine n=1355; on-tr
Nausea 438 (31·9%) 19 (1·4%)
- orforglipron 36 mg or MTD · vomiting · Table 3 (orforglipron n=1371, insulin glargine n=1355; on-tr
Vomiting 288 (21·0%) 22 (1·6%)
- orforglipron 36 mg or MTD · sae · Table 3 (orforglipron n=1371, insulin glargine n=1355; on-tr
Serious adverse events 222 (16·2%) 255 (18·8%)
Cardiovascular and kidney outcomes
ACHIEVE-4 orforglipron 36 mg or maximum tolerated dose (oral, once daily) vs insulin glargine (active) · T2D at increased CV risk (86 % established CVD, 38 % CKD) · n = 2749 · 2026 verified
| Endpoint | HR | 95 % CI | Events, drug vs control | Status |
|---|---|---|---|---|
| 4-point MACE primary MACE-4: composite of non-fatal myocardial infarction, non-fatal stroke, hospitalisation for unstable angina, or cardiovascular death (primary endpoint; non-inferiority, safety analysis set) | 0.84 | 0.59–1.20 | 57 vs 67 | verified |
| 3-point MACE MACE-3: composite of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death (key secondary endpoint; superiority, randomised participants excluding GCP-closed sites) | 0.77 | 0.52–1.13 | 46 vs 59 | verified |
| Cardiovascular death Cardiovascular death (component of MACE-4; deaths of undetermined cause counted as CV deaths) | 0.47 | 0.25–0.90 | 14 vs 29 | verified |
| Myocardial infarction Non-fatal myocardial infarction (component of MACE-4) — non-fatal events only | 0.85 | 0.46–1.58 | 19 vs 22 | verified |
| Stroke Non-fatal stroke (component of MACE-4) — non-fatal events only | 0.98 | 0.47–2.06 | 14 vs 14 | verified |
| Hospitalisation for unstable angina Hospitalisation for unstable angina (component of MACE-4) | 1.55 | 0.67–3.58 | 14 vs 9 | verified |
Verbatim quotes (6)
- 4-point MACE · Table 2
p value MACE-4 (primary endpoint)* 57/1358 (4·2%) 67/1343 (5·0%) 0·84 (0·59-1·20)
- 3-point MACE · Table 2
47-2·06) ·· Hospitalisation for unstable angina 14/1358 (1·0%) 9/1343 (0·7%) 1·55 (0·67-3·58) ·· MACE-3 (key secondary endpoint)* 46/1358 (3·4%) 59/1366 (4·3%) 0·77 (0·52-1·13)
- Cardiovascular death · Table 2
p value MACE-4 (primary endpoint)* 57/1358 (4·2%) 67/1343 (5·0%) 0·84 (0·59-1·20) <0·0001 (non- inferiority) Cardiovascular death 14/1358 (1·0%) 29/1343 (2·2%) 0·47 (0·25-0·90)
- Myocardial infarction · Table 2
<0·0001 (non- inferiority) Cardiovascular death 14/1358 (1·0%) 29/1343 (2·2%) 0·47 (0·25-0·90) ·· Non-fatal myocardial infarction 19/1358 (1·4%) 22/1343 (1·6%) 0·85 (0·46-1·58)
- Stroke · Table 2
343 (2·2%) 0·47 (0·25-0·90) ·· Non-fatal myocardial infarction 19/1358 (1·4%) 22/1343 (1·6%) 0·85 (0·46-1·58) ·· Non-fatal stroke 14/1358 (1·0%) 14/1343 (1·0%) 0·98 (0·47-2·06)
- Hospitalisation for unstable angina · Table 2
(1·6%) 0·85 (0·46-1·58) ·· Non-fatal stroke 14/1358 (1·0%) 14/1343 (1·0%) 0·98 (0·47-2·06) ·· Hospitalisation for unstable angina 14/1358 (1·0%) 9/1343 (0·7%) 1·55 (0·67-3·58)
Primary sources
- Klein KR, Wysham C, Tuttle KR, Davies MJ, Cox D, Chen J, et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial. Lancet. 2026. PMID: 42815506.
- Eli Lilly and Company. A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4). ClinicalTrials.gov identifier NCT05803421. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05803421
How to cite this page
Medical Adviser's Group. Incretin Atlas: ACHIEVE-4. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/achieve-4/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.